Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103469 | 1.00 | CCR3 (0.47) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL3840449 | 0.88 | CCR3 (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL9001749 | 0.88 | CCR3 (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL29449914 | 0.86 | CCR3 (0.46) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL1635974 | 0.86 | CCR3 (0.46) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL17103611 | 0.82 | CCR3 (0.44) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL17103610 | 0.82 | CCR3 (0.44) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL13744920 | 0.82 | ACHE (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL14506645 | 0.82 | ACHE (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL14492207 | 0.82 | ACHE (0.51) | CCR3CCR5ABL1RIN1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370375-B2 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | ELANCO TIERGESUNDHEIT AG (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180346465-A1 | New Compounds | ELANCO TIERGESUNDHEIT AG (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3122731-B1 | CYCLOHEXYLMETHANSULFONAMIDES | ELANCO TIERGESUNDHEIT AG (CH) | 2018-10-10 | — | — | EP | disclosed |
| US-10059709-B2 | Compounds | ELANCO TIERGESUNDHEIT AG (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20170050965-A1 | New Compounds | ELANCO TIERGESUNDHEIT AG (CH) | 2017-02-23 | — | — | US | disclosed |
| EP-2924026-A1 | Aminosulfonylmethylcyclohexanes as JAK inhibitors | Novartis Tiergesundheit AG (CH) | 2015-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346465-A1 | New Compounds | HLA-DRB1, SLC10A1, NFATC1 | CCR3 719/4885CCR5 333/4885ABL1 2836/4885 |
| US-10370375-B2 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | JAK1, JAK3, JAK2 | CCR3 1073/4885CCR5 846/4885ABL1 300/4885 |
| US-20170050965-A1 | New Compounds | HLA-DRB1, SLC10A1, NFATC1 | CCR3 704/4885CCR5 324/4885ABL1 2886/4885 |
| US-10059709-B2 | Compounds | HLA-DRB1, SLC10A1, ITCH | CCR3 494/4885CCR5 341/4885ABL1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.